title: Ethmoid sinus cancer: results of treatment with surgery and combined therapy.
abstract: OBJECTIVE
  Ethmoid sinus cancer is a rare paranasal sinus malignancy. Its characteristics include a low incidence rate, a great variety of histopathological types and multiple treatment modalities. Currently, there remains no definite consensus regarding its optimal management. The aim of this study was to examine the outcome of a population of Asian patients with advanced ethmoid sinus cancers that had been treated with surgery plus combined therapy.
  
  
  METHODS
  Between January 1989 and December 2002 inclusive, 19 newly diagnosed patients with ethmoid sinus cancers who had undergone surgical intervention were enrolled, T4 being the principal carcinoma stage (68.4%). All participating cases proved to be node-negative and no evidence of any distant metastasis was detected at the time of diagnosis. The major treatment modality was surgery plus postoperative radiotherapy. All but 2 of the 13 patients with T4 cancer underwent craniofacial resection with pericranial flap reconstruction.
  
  
  RESULTS
  The estimated overall and disease-free survival rates 3 years post-treatment were 49.4% and 26.3%, respectively. Local tumor recurrence was more common than regional recurrence and/or distant metastasis. A total of 5/15 T3-T4 patients (33%) developed a neck metastasis, 3 of whom also suffered a distant metastasis. There was no postoperative mortality for the cases treated with craniofacial resection.
  
  
  CONCLUSIONS
  Ethmoid sinus cancer typically demonstrates a propensity for late diagnosis and poor prognosis. This study confirms that craniofacial resection plus combined associated therapy is the optimal approach for the effective management of extensive ethmoid sinus tumors and is associated with an acceptable morbidity rate. More aggressive disease management featuring prophylactic concurrent chemoradiotherapy including neck or elective neck dissection plus chemotherapy should be considered for T3-T4 patients as opposed to T1-T2 patients.
authors.affiliation: Department of Otolaryngology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
authors.forename: Cheng-Yu
authors.initials: CY
authors.lastname: Lin
authors.forename: Helen H W
authors.initials: HH
authors.lastname: Chen
authors.forename: Hsing-Hong
authors.initials: HH
authors.lastname: Chen
authors.forename: Sheen-Yie
authors.initials: SY
authors.lastname: Fang
authors.forename: Sen-Tien
authors.initials: ST
authors.lastname: Tsai
mesh_terms: D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005005:Ethmoid Sinus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010255:Paranasal Sinus Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D015996:Survival Rate